PTC Therapeutics, Inc. announced on 31st March 2022 the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with Huntington’s disease (HD). PIVOT-HD is a global trial starting in the United States. PTC518 is an oral, small molecule splicing modifier that was specifically designed to selectively lower huntingtin mRNA and protein. There…
Innovative IQoro neuromuscular treatment device achieves NHS prescription status
IQoro, a treatment device for swallowing dysfunction and acid-reflux based diseases, will be added to the Drug Tariff from May 1st this year. It has previously been used by around 75,000 individuals that have self-purchased, and by SLTs and neuro-rehab clinicians in 40 or more NHS trusts. IQoro is a simple hand-held device that is…
CTE Biobank launches in Australia
A national biobank to collect information and test samples relating to repeated traumatic brain injuries often associated with sport was launched on 22nd March 2022 in Australia, with New Zealand announcing its intention to establish a similar clinic and biobank. Chronic traumatic encephalopathy (CTE) is a form of dementia that results from repeated head injuries, and is…
Call For Evidence Consultation Launched For ABI Strategy
A Call for Evidence has been launched for the recently agreed cross departmental Government strategy for Acquired Brain Injury (ABI). The UK Acquired Brain Injury Forum (UKABIF) joined other brain injury charities and organisations and people with acquired brain injury at the House of Commons this week where the Minister of State for Care and…
WFNR Franz Gerstenbrand Award 2022
Brain Awareness Week – WFNR Franz Gerstenbrand Award 2022 now open for entries As we mark Brain Awareness Week, I’m delighted to announce that the World Federation for Neurorehabilitation (WFNR) Franz Gerstenbrand Award 2022 is now open, and we particularly encourage entries from individuals under the age of 35 years who are clinicians, researchers or…
Music Therapy strikes a chord with traumatised emergency workers
The Blue Light Symphony Orchestra (BLSO), in collaboration with Chroma, successfully completed a pilot project delivering group Music Therapy to emergency service workers to help them recover from traumatic experiences. Working with Surrey and Sussex Police, Surrey and East Sussex Fire and Rescue and Southeast Coast Ambulance Service, the project, a UK first, delivered a…
Copaxone® for use in breastfeeding mothers with RMS
Change to COPAXONE® (Glatiramer Acetate (GA)) Summary of Product Characteristics (SmPC) in breastfeeding is relevant for the Multiple Sclerosis (“MS”) community and provides information for neurologists and patients of the positive benefit/risk balance of use in breastfeeding Relapsing Multiple Sclerosis (RMS) is 2-3 times more likely to affect womeni, with diagnosis most common during childbearing years The SmPC update…
UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results
Positive topline results show the Phase 3 RAISE (NCT04115293) zilucoplan trial met primary and all key secondary endpoints in adults with generalised myasthenia gravis The results show a favourable safety profile and good tolerability UCB plans to proceed with zilucoplan regulatory submissions later this year Results follow recent positive topline data from the Phase…
UKABIF Award Winners Announced at Time for Change Summit
The winners of the annual UK Acquired Brain Injury Forum (UKABIF) awards have been honoured at this year’s Time for Change summit. The Awards include the UKABIF Film Award, the Mike Barnes Award for Innovation, the Stephen McAleese Award for Inspiration and the UKABIF Poster Award. The Awards were kindly sponsored by Elysium Healthcare. Nicola…
